by admin | 15th August 2023 | News
London and New York, NY, August 15 2023 – OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market,... by admin | 31st July 2023 | News
LONDON and NEW YORK, July 31, 2023 — OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this...
by admin | 28th July 2023 | News
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP Second clinical indication for OK-101 which is currently in 240 patient phase 2 clinical... by admin | 6th June 2023 | News
Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain component Top-line data from trial anticipated in Q4, 2023 London and New York, NY, June 6, 2023 – OKYO Pharma Limited (NASDAQ: OKYO), an... by admin | 22nd May 2023 | News
OKYO Pharma Limited (“OKYO” or “Company”) London Stock Exchange Delisting 22 May 2023 Further to the Dealing Announcement published by the FCA this morning, the board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), confirm the...
